Accent Clinical Trial Overview

Amplia Therapeutics is developing a class of drug called a FAK inhibitor.

Who We Are

About Amplia

Amplia is developing a class of drug called a FAK inhibitor which we hope will make cancers more vulnerable and responsive to currently used treatments.

Amplia has successfully navigated vital research and development milestones to get to this stage. Our clinical trial sites in Australia and South Korea are active but no longer recruiting participants for our ACCENT trial as we test if narmafotinib in combination with standard of care drugs gemcitabine and nab-paclitaxel (also known as Abraxane®) is effective in treating cancer.

About the clinical trial

The ACCENT Clinical Trial (AMP945-PC-201) has strict entry criteria. All enquiries for involvement must be made via our clinical trial sites.

The trial is active but not recruiting

Clinical trial sites are located in Brisbane, Sydney and Melbourne, Australia and South Korea. See below.

The ACCENT trial will test if narmafotinib helps people with pancreatic cancer have a better response to standard of care chemotherapies, gemcitabine and nab-paclitaxel.

Narmafotinib aims to break down the fibrotic tissue shield in pancreatic cancer to allow the chemotherapy to be more effective.

Locations

Need more information?

We recommend discussing treatment options directly with your oncologist. Follow Amplia Therapeutics for key clinical and commercial updates too.

Study Details | ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer | ClinicalTrials.gov